Picture of Amgen logo

AMGN Amgen Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Amgen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue23,36225,42425,97926,32328,190
Cost of Revenue
Gross Profit19,00619,26519,52519,91719,775
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses13,68816,28518,34016,67920,068
Operating Profit9,6749,1397,6399,6448,122
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes9,1388,1336,7017,3467,855
Provision for Income Taxes
Net Income After Taxes7,8427,2645,8936,5526,717
Net Income Before Extraordinary Items
Net Income7,8427,2645,8936,5526,717
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income7,8427,2645,8936,5526,717
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS12.912.312.912.912.6
Dividends per Share